2,784 vaccinations later
April 29, 2011 By Jonathan Wood in Medications
Mothers and babies taking part in the trial in South Africa.
The two thousand, seven hundred and eighty-fourth baby has been vaccinated today in South Africa as part of a clinical trial of a new vaccine against tuberculosis. The new TB vaccine is the most advanced in development anywhere in the world.
Thats the last baby in the trial, and marks completion of trial enrolment almost two years to the day after the study was first announced.
"We are extremely proud of this achievement and are eager to see the study results, which are expected to be available in 2012," says Dr. Helen McShane, who developed the vaccine at the Jenner Institute, Oxford University. "This milestone brings us a step closer to potentially having a new TB vaccine, from which millions of people around the world would benefit."
Its certainly quite a milestone, and marks a great deal of work to vaccinate all these babies under 1 year old in an area where there is one of the highest rates of TB in the world.
But why precisely 2,784 babies, not 2,500 or 3,000?
Helen explains that it is entirely down to the calculations used to plan the trial. These sums showed that 2784 babies should give enough statistical weight to be able to see a significant improvement in preventing TB over the 90-year-old (but still standard) BCG jab.
The new vaccine is designed to be given to infants after they have received the BCG vaccine, boosting the immune response further. All the babies in the trial have received the BCG vaccine, with half then getting the trial vaccine and half a placebo. "If successful, the next steps would be to plan a phase III trial and licensure of the vaccine," Helen says.
The current trial was a phase IIb trial, and is the first to be able to really determine whether the vaccine gives infants any protection against TB. A larger phase III trial would pin down exactly the size of any benefit and guide how the vaccine could be rolled out.
The trial in Worcester, about 100km from Cape Town, is being conducted by the University of Cape Towns South African Tuberculosis Vaccine Initiative (SATVI), in partnership with Aeras, the Wellcome Trust, and the Oxford-Emergent Tuberculosis Consortium Ltd (a joint venture between the University of Oxford and Emergent Biosolutions Inc formed to develop the vaccine)
"We are pleased to report that the trial has run smoothly to date," says Dr. Hassan Mahomed, who has led the trial at SATVI.
Provided by
Oxford University
-
TB vaccine enters new clinical trials
Apr 23, 2009 |
not rated yet |
0
-
New TB booster shows promise
Mar 16, 2010 |
not rated yet |
0
-
Tuberculosis vaccine passes phase I trial
Mar 24, 2011 |
not rated yet |
0
-
New TB vaccine enters clinical testing
Sep 23, 2010 |
not rated yet |
0
-
Trials begin for 'essential' new TB vaccine
Jul 30, 2007 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013
-
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
- More from Physics Forums - Medical Sciences
More news stories
Feds fight morning-after pill age ruling in NY
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
Medications
12 hours ago |
not rated yet |
0
Merck ends development of Parkinson's disease drug
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications
May 23, 2013 |
1 / 5 (1) |
0
J&J expects 10-plus new drug applications by 2017
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications
May 23, 2013 |
5 / 5 (1) |
0
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications
May 22, 2013 |
not rated yet |
0
Glaxo, US partnering to develop new antibiotics
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications
May 22, 2013 |
not rated yet |
0
First drug to improve heart failure mortality in over a decade
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
Seniors more likely to crash when driving with pet, study finds
(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...
Heart failure accelerates male 'menopause'
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
Death highest in heart failure patients admitted in January, on Friday, and overnight
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
New immune system discovered
(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.
Brain can be trained in compassion, study shows
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.